One way to enhance tumor-specific T cell responses is to use agonistic antibodies that engage T cell costimulatory receptors, including cluster of differentiation proteins (CD)137 (4-1BB), CD27 and CD134 (OX40). This evidence concerns the gene CTLA4 and neoplasm.